Kymera Therapeutics Enters Material Definitive Agreement
Ticker: KYMR · Form: 8-K · Filed: Aug 20, 2024 · CIK: 1815442
| Field | Detail |
|---|---|
| Company | Kymera Therapeutics, Inc. (KYMR) |
| Form Type | 8-K |
| Filed Date | Aug 20, 2024 |
| Risk Level | medium |
| Pages | 6 |
| Reading Time | 7 min |
| Key Dollar Amounts | $0.0001, $40.75, $40.7499, $246.5 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, filing
Related Tickers: KYMR
TL;DR
Kymera signed a big deal, filing an 8-K. Details to come.
AI Summary
Kymera Therapeutics, Inc. announced on August 19, 2024, that it entered into a material definitive agreement. The company also reported other events and filed financial statements and exhibits. Specific details of the agreement and financial information were not provided in this initial filing.
Why It Matters
This filing indicates a significant business development for Kymera Therapeutics, potentially impacting its strategic direction and financial future.
Risk Assessment
Risk Level: medium — Material definitive agreements can carry significant financial and operational risks depending on their nature and terms.
Key Players & Entities
- Kymera Therapeutics, Inc. (company) — Registrant
- August 19, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-39460 (file_number) — Commission File Number
- 81-2992166 (tax_id) — I.R.S. Employer Identification No.
- 500 North Beacon Street, 4th Floor (address) — Principal executive offices
- Watertown, Massachusetts 02472 (address) — Principal executive offices
- (857) 285-5300 (phone_number) — Registrant's telephone number
FAQ
What is the nature of the material definitive agreement entered into by Kymera Therapeutics?
The filing states that Kymera Therapeutics, Inc. entered into a material definitive agreement on August 19, 2024, but does not provide specific details about the agreement itself.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on August 19, 2024.
What is Kymera Therapeutics, Inc.'s principal executive office address?
Kymera Therapeutics, Inc.'s principal executive office is located at 500 North Beacon Street, 4th Floor, Watertown, Massachusetts 02472.
What is the Commission File Number for Kymera Therapeutics, Inc.?
The Commission File Number for Kymera Therapeutics, Inc. is 001-39460.
What other items are reported in this 8-K filing besides the material definitive agreement?
In addition to the entry into a material definitive agreement, this 8-K filing also reports on other events and includes financial statements and exhibits.
Filing Stats: 1,718 words · 7 min read · ~6 pages · Grade level 11.7 · Accepted 2024-08-20 17:24:59
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share KYMR The Nasdaq
- $40.75 — on Stock"), at a price to the public of $40.75 per share, and (b) pre-funded warrants
- $40.7499 — Warrants"), at a price to the public of $40.7499 per warrant, which represents the per s
- $246.5 million — ffering expenses, will be approximately $246.5 million. The Company also may receive nominal p
Filing Documents
- d846843d8k.htm (8-K) — 38KB
- d846843dex11.htm (EX-1.1) — 212KB
- d846843dex41.htm (EX-4.1) — 75KB
- d846843dex51.htm (EX-5.1) — 10KB
- d846843dex991.htm (EX-99.1) — 10KB
- d846843dex992.htm (EX-99.2) — 11KB
- g846843g0820102031754.jpg (GRAPHIC) — 3KB
- 0001193125-24-203755.txt ( ) — 571KB
- kymr-20240819.xsd (EX-101.SCH) — 3KB
- kymr-20240819_lab.xml (EX-101.LAB) — 18KB
- kymr-20240819_pre.xml (EX-101.PRE) — 11KB
- d846843d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits. Exhibit No. Description 1.1 Underwriting Agreement, dated August 19, 2024, by and among Kymera Therapeutics, Inc. and Morgan Stanley & Co. LLC, J.P. Morgan Securities LLC, TD Securities (USA) LLC and Stifel, Nicolaus & Company, Incorporated. 4.1 Form of Pre-Funded Warrant. 5.1 Opinion of Goodwin Procter LLP. 23.1 Consent of Goodwin Procter LLP (contained in Exhibit 5.1). 99.1 Launch Press Release dated August 19, 2024, furnished herewith. 99.2 Pricing Press Release dated August 19, 2024, furnished herewith. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Kymera Therapeutics, Inc. Date: August 20, 2024 By: /s/ Nelo Mainolfi Nello Mainolfi, Ph. D. President and Chief Executive Officer